Rubicon Research Ltd has filed the Scheme of Amalgamation to merge its wholly owned subsidiary, Kia Health Tech Private Limited, with itself under Section 233 of the Companies Act, 2013. The appointed date for the merger is April 1, 2026. As the transferor company is a wholly owned subsidiary, no shares will be issued, and no consideration will be payable, resulting in no change to the shareholding pattern or voting rights of the company. The scheme is subject to statutory, regulatory, shareholder, and creditor approvals.

The Board of Directors approved the scheme at a meeting held on July 20, 2026. The merger aims to achieve business synergy, pool resources, and optimise existing capabilities into a single entity. It is expected to result in economies of scale, reduction in overheads, and better utilisation of financial and human resources. The amalgamation will also reduce multiplicity of legal and regulatory compliances and augment the manufacturing footprint of Rubicon Research.

Key Corporate Actions

Capital Structure Changes

The authorised share capital of Rubicon Research will increase from ₹23,89,90,000 to ₹40,69,90,000 divided into 40,69,90,000 equity shares of Re. 1 each upon the merger of the authorised share capital of Kia Health Tech. The issued, subscribed, and paid-up share capital of the transferor company consists of 88,00,000 equity shares of ₹10 each, amounting to ₹880.00 lakh. The increase in the transferee company's issued capital as of June 30, 2026, was due to the exercise of employee stock options.

Merger Rationale

The proposed amalgamation is intended to facilitate the pooling of resources and exploit growth potential by combining activities under a single entity. It will enable better cash management and unfettered access to cash flow generated by the combined business. The merger will also help in rationalising vendors, aggregating purchase quantity, and managing the procurement supply chain more effectively. The scheme is conditional upon the approval of members and creditors, sanction by the Regional Director, and requisite consents from governmental authorities.

Rubicon Research has expanded its global footprint with the acquisition of a manufacturing facility in the United States for an enterprise value of USD 2.9 million. The company’s wholly owned subsidiary, AdvaGen Holdings, purchased the site in East Brunswick, New Jersey, from InvaTech Pharma Solutions, LLC. This strategic move establishes a US manufacturing base comparable in size to Rubicon’s existing facility in Satara, strengthening its supply chain resilience and proximity to customers.

The acquisition was completed on July 21, 2026, following a court-supervised competitive bid process under Section 363 of the U.S. Bankruptcy Code. As part of the transaction, AdvaGen Holdings has assumed the facility's lease and taken possession of all associated equipment, records, and permits. The site does not include any product approvals or filings.

The operational facility specializes in manufacturing oral solid and oral liquid formulations. It has maintained a USFDA inspection record for over a decade, marked by three successful inspections. The USFDA conducted an unannounced inspection in May 2026, resulting in a Form 483 with six observations. The company stated these observations were procedural and unrelated to data integrity, adding that corrective actions have been completed to facilitate a timely conclusion.

Looking ahead, the site will focus on producing specialty and high-value products, catering to demand from US government departments. Rubicon Research plans to commence manufacturing at the facility in calendar year 2027, pending the implementation of its quality management systems. Parag Sancheti, CEO of Rubicon Research, highlighted that the acquisition complements the company's growing portfolio and enhances agility in its global supply chain.